



Biotech Daily

SPECIAL SUMMER CATCH-UP EDITION

Sunday, January 19, 2020

The Summer Catch-Up Edition was compiled by Rebekah Andrews

- * SIENNA RIGHTS RAISE \$263k OF HOPED-FOR \$2.5m, TOTAL \$2m
- * CARDIEX \$1.5m FROM C2 VENTURES
- * AUSCANN: MAX JOHNSTON, KRISTA BATES IN; CHERYL EDWARDES OUT
- * AUSTRALIAN ETHICAL REDUCES TO 15% OF ANTISENSE
- * ORBIS (ALLAN GRAY) CEASES IN PHARMAXIS
- * PRESCIENT CLAIMS 91% PTX-200 BREAST CANCER RESPONSE RATE
- * NOVITA CHANGES NAME TO TALI DIGITAL
- * TELIX RECRUITING TLX101 GLIOBLASTOMA TRIAL
- * CLINUVEL FILES SCENESSE TGA REGISTRATION APPLICATION
- * ALLEGRA RECEIVES UNI OF SYDNEY, NHMRC \$786k GRANT
- * INVION CFO MELANIE FARRIS REPLACES DIRECTOR, DR JAMES CAMPBELL
- * PLATINUM REDUCES TO 5% OF ANTISENSE
- * EMPERY BELOW 5% IN BENITEC
- * LIFESPOT STARTS SLIM LINE MARIJUANA VAPORIZER PRODUCTION
- * ELLEX: LUMIBIRD PAYS \$100m FOR LASER, ULTRASOUND BUSINESS
- * IDT TERMINATES US TEMOZOLOMIDE MAYNE DISTRIBUTION DEAL
- * IMUGENE COMPLETES UNMARKETABLE PARCEL SALE
- * MICRO-X RAISES \$16.5m IN 'OVERSUBSCRIBED' OFFER
- * INVION TO SUPPLY DERMATOLOGY COMPOUND FOR CHINA'S PAVAY
- * TELIX FILES PHASE III TLX250-CDX KIDNEY CANCER FDA IND APPLICATION
- * KAZIA RECEIVES \$1.4m R&D TAX INCENTIVE

- * ORTHOCELL SHARE PLAN RAISES \$1.4m; TOTAL \$14.4m
- * ALCIDION \$1.9m DEAL WITH DARTFORD, GRAVESHAM NHS TRUST
- * TELIX SUBMITS TLX591-CDx CLINICAL BRIEFING PACKAGE TO US FDA
- * DAVID HANNON, DRH SUPER BELOW 5% IN NOXOPHARM
- * PRO MEDICUS, NINES \$6m VISAGE 7 DEAL
- * VISIONEERING \$3m PLACEMENT TO THORNEY
- * FDA APPROVES AVITA RECELL FOR VITILIGO STUDY
- * DORSAVI RAISES \$187k IN SHARE PLAN; TOTAL RAISED \$1.9m
- * STARPHARMA PHASE I AZD0466 TRIAL FOR CANCER; \$4.3m MILESTONE
- * INVITROCUE TELLS ASX QUERY: DR LINDNER 'NOT THEN A DIRECTOR'
- * CRESO DRAWS DOWN \$518k OF CONVERTIBLE NOTE FACILITY
- * KARST PEAK, VERMILLION, ADAM LEITZES TAKE 12% OF CYCLOPHARM
- * JENCAY CAPITAL TAKES 6% OF ELLEX
- * IMAGION PLEADS SCHULTZ TO 21% ASX PRICE QUERY
- * PRESCIENT FOUNDER, DIRECTOR PAUL HOPPER STEPS DOWN
- * NUHEARA APPOINTS CHERYL EDWARDES CHAIR
- * REDHILL ENDS 2014 SALIX LICENCE
- * AUSTRALIAN ETHICAL TAKES 10% OF CYCLOPHARM
- * CVC REDUCES TO 9% OF CYCLOPHARM
- * MESOBLAST FILES FDA REMESTEMCEL-L DATA
- * ANTISENSE OPTIONS RAISE \$5.5m
- * ROBERT BAZZANI REPLACES MACH7'S DAMIEN LIM, JENNIFER PILCHER
- * ADALTA LOSES DIRECTOR DR JOHN CHIPLIN
- * USCOM 5-YEAR CHINA NMPA APPROVAL FOR USCOM 1A
- * CELLMID US, EURO MIDKINE PATENTS
- * NUHEARA LAUNCHES IQBUDS MAX, TO BEGIN SHIPPING IN MARCH
- * OPTHEA RECRUITS OPT-302 COMBO TRIAL FOR DME

- * PHARMAUST EPICHEM CLIENT UNITY BIOTECHNOLOGY ENDS CONTRACT
- * POLYNOVO: '\$2m NOVOSORB BTM DECEMBER SALES'
- * MGC AUSTRALIA, NEW ZEALAND MARIJUANA MERCURY PHARMA
- * CYNATA RECEIVES \$1.9m R&D TAX INCENTIVE
- * DIMERIX 'NO SAFETY CONCERNS IN DMX-200 TRIALS'
- * CANN GROUP, IDT MARIJUANA RESIN EXTRACTION UNDERWAY
- * ALTHEA BEATS 4k MARIJUANA PATIENT TARGET
- * PHARMAUST EPICHEM EXTENDS DNDI CONTRACT TO DEC 31, 2020
- * ELIXINOL RELEASES 78m SHARES FROM ASX ESCROW
- * CRESO PLEADS SCHULTZ TO ASX 24% QUERY
- * CRESO RELEASES 500k SHARES FROM VOLUNTARY ESCROW
- * IMMUTEP EXPANDS IMP321 TACTI-002 CANCER STUDY
- * ADHERIUM APPOINTS JANE LAPON MARKET ACCESS HEAD
- * MGC: 2k MARIJUANA SCRIPTS; 1st SHIPMENT IN BRAZIL
- * ELI LILLY PAYS \$1.6b FOR TOM WIGGANS' DERMIRA
- * THORNEY, TIGA TRADING TAKE 15% OF VISIONEERING
- * REGAL FUNDS INCREASES, DILUTED TO 14% OF VISIONEERING
- * ANDREAS EMPL REPLACES LIFESPOT DIRECTOR GREG PLUNKETT
- * AVECHO: EX-BIOSCIENCE MANAGERS MATT MCNAMARA DIRECTOR
- * ESENSE APPOINTS DR JAMES ELLINGFORD DIRECTOR
- * TOTAL BRAIN APPOINTS DAVID DAGLIO DIRECTOR
- * ANTEOTECH PLEADS SCHULTZ TO ASX 72% QUERY
- * ANGLO CHARITABLE INCREASES, DILUTED TO 17% OF CYCLOPHARM
- * RACE DR AL-BEHAISI CONTRACT ENDS; TO RECRUIT AUSTRALIAN CRM
- * MMJ \$2.2m HARVEST ONE CANNABIS LOAN AGREEMENT
- * UK APPROVES CYNATA CYMERUS CRITICAL LIMB ISCHAEMIA TRIAL
- * CE MARK FOR PROTEOMICS PROMARKERD HUB

- * ADALTA PHASE I AD-214 TRIAL DELAYED FOR MORE DATA
- * EURO ORPHAN STATUS FOR ALTERITY PBT434 FOR MSA
- * IMUGENE: US GRANTS HER-VAXX CANCER IMMUNOTHERAPY PATENT
- * ESCROW END TAKES RAW WITH LIFE, ELIXINOL'S PAUL BENHAIM TO 40%
- * INVESTORS MUTUAL REDUCES TO 6% OF ELLEX
- * KARST PEAK, ADAM LEITZES, VERMILLION REDUCE TO 6% OF AVITA
- * PHARMAUST RECEIVES \$713k R&D TAX INCENTIVE
- * GI DYNAMICS RECEIVES \$6.7m FROM CRYSTAL AMBER CONVERTIBLE NOTE
- * REVA FILES US CH 11 BANKRUPTCY
- * GI DYNAMICS: ENDOBARRIER 'SIGNIFICANTLY' REDUCES C-V RISK
- * KARIN LINDGREN REPLACES VOLPARA DIRECTOR PROF MIKE BRADY
- * BARINGS DILUTED TO 15% OF CYCLOPHARM
- * ALTERITY RECEIVES \$4.8m R&D TAX INCENTIVE
- * ORTHOCELL RECEIVES \$2.9m R&D TAX INCENTIVE
- * JAPAN PATENT FOR PAINCHEK SMART PHONE PAIN TEST
- * TALI: GOOGLE FOR EDUCATION PARTNER STATUS
- * NAOS TAKES 22% OF BTC HEALTH
- * STEMCELL UNITED PLEADS SCHULTZ TO ASX 85% QUERY
- * ASX QUERIES VISIONEERING CASH BURN
- * NOXOPHARM'S NYRADA IPO OPENS UP 52.5%
- * LIFESPOT CAPITAL AG REDUCES TO 18% OF LIFESPOT
- * G MEDICAL COMPLETES CHINA TRIALS FOR PRIZMA APPROVAL
- * OBJ 'WELLFULLY' \$50m BACKDOOR, 20-TO-ONE CONSOLIDATION EGM
- * MERCHANT FUNDS MANAGEMENT BELOW 5% IN ZELIRA

Detailed summaries continue on the following pages

The following articles appear in date order

Late on Friday December 20, 2019

SIENNA RIGHTS RAISE \$263k OF HOPED-FOR \$2.5m, TOTAL \$2m

[SIENNA CANCER DIAGNOSTICS](#)

Sienna says it has raised \$262,587.62 of a hoped for \$2.5 million in a non-renounceable rights issue, for a total \$1.9 million raised at 3.5 cents a share. Last year, Sienna said it hoped to raise up to \$4.2 million through a \$1.7 million placement and \$2.5 million rights issue (BD: Nov 29, 2019).

CARDIEX \$1.5m FROM C2 VENTURES

[CARDIEX](#)

Cardiex says it has raised \$1.5 million in additional funding, following commitments from C2 Ventures, a related company to chairman Niall Cairns and chief executive officer Craig Cooper, with the new shares to be issued at 2.75 cents a share, with a one for four attaching listed option at an exercise price of 5.0 cents a share.

AUSCANN: MAX JOHNSTON, KRISTA BATES IN; CHERYL EDWARDES OUT

[AUSCANN GROUP HOLDINGS](#)

Auscann says it has appointed Max Johnston and Krista Bates as non-executive directors effective immediately and Mr Johnston chairman from January 19, 2020.

AUSTRALIAN ETHICAL REDUCES TO 15% OF ANTISENSE

[ANTISENSE THERAPEUTICS](#)

Australian Ethical Investment says it has reduced its substantial shareholding in Antisense from 67,610,264 shares (16.04%) to 66,929,488 shares (14.57%). The Sydney-based Australian Ethical said it sold 680,776 shares for \$74,721 or 11.0 cents a share.

ORBIS (ALLAN GRAY) CEASES IN PHARMAXIS

[PHARMAXIS](#)

Orbis Investment Management (Allan Gray) says it has ceased to be a substantial shareholder in Pharmaxis, buying and selling shares between November 1 and December 18, 2019.

Monday December 23, 2019

PRESCIENT CLAIMS 91% PTX-200 BREAST CANCER RESPONSE RATE

[PRESCIENT THERAPEUTICS](#)

Prescient says its 11-patient, phase IIa trial of PTX-200 for human epidermal growth factor receptor 2 (HER2) breast cancer has an overall response rate of 91 percent. Prescient said that of the 10 patients evaluable for the study responded to therapy, two had pathologic complete responses, one patient had a clinical complete response and the remaining eight had "pathological partial responses".

The company said patients had an average progression-free survival of 22 months so far and of up to 40 months in total, and it planned to begin a new trial to focus on patients with estrogen-receptor-positive (ER positive) disease.

NOVITA CHANGES NAME TO TALI DIGITAL

[TALI DIGITAL \(FORMERLY NOVITA HEALTHCARE\)](#)

Novita says its name change to Tali Digital Limited has been approved and it will begin trading under the code TD1 from December 30, 2019.

TELIX RECRUITING TLX101 GLIOBLASTOMA TRIAL

[TELIX PHARMACEUTICALS](#)

Telix says five of six trial sites are open and recruiting for both single and multi-dose cohorts of its phase I/II trial of TLX101 with radiotherapy for recurrent glioblastoma. Telix said the Australian site was expected to open in early 2020 and it expected to complete the first dose escalation phase by July 2020, with a mid-2020 readout for US Food and Drug Administration and European Medicines Agency consultations.

CLINUVEL FILES SCENESSE TGA REGISTRATION APPLICATION

[CLINUVEL PHARMACEUTICALS](#)

Clinuvel says it has submitted an Australian Therapeutic Goods Administration registration for Scenesse for erythropoietic protoporphyria.

ALLEGRA RECEIVES UNI OF SYDNEY, NHMRC \$786k GRANT

[ALLEGRA ORTHOPAEDICS](#)

Allegra says it will receive \$786,000 from the University of Sydney through the National Health and Medical Research Council Development grants.

Allegra said it would receive the funding to contribute towards a pre-clinical study for a clinically proven, market-ready, synthetic scaffold material for spinal fusion, which would lead to a small confirmatory human clinical trial in Australia.

INVION CFO MELANIE FARRIS REPLACES DIRECTOR, DR JAMES CAMPBELL

[INVION](#)

Invion says it has appointed chief financial officer and company secretary Melanie Farris as a director and director Dr James Campbell has retired effective from December 21, 2019.

PLATINUM REDUCES TO 5% OF ANTISENSE

[ANTISENSE THERAPEUTICS](#)

Platinum Investment Management says it has reduced its substantial shareholding in Antisense from 26,335,114 shares (6.27%) to 23,655,381 shares (5.15%).

The Sydney-based Platinum said it sold 2,679,733 shares for \$267,973.30 or 10.0 cents a share.

EMPERY BELOW 5% IN BENITEC

[BENITEC BIOPHARMA](#)

The New York-based Empery Tax Efficient says it has ceased to be a substantial shareholder in Benitec after it sold 25,000,000 shares on December 18, 2019.

Benitec

LIFESPOT STARTS SLIM LINE MARIJUANA VAPORIZER PRODUCTION

[LIFESPOT HEALTH](#)

Lifespot says it has received the deposit to commence tooling and production of a new slim line smart vaporizer for marijuana-based Ionic Brands in the US.

Tuesday December 24, 2019 (Christmas Eve)

ELLEX: LUMIBIRD PAYS \$100m FOR LASER, ULTRASOUND BUSINESS

[ELLEX MEDICAL LASERS](#)

Ellex says the Lannion, France-based Lumibird Group SA will pay \$100 million cash for its lasers and ultrasound business.

Ellex said Lumibird would acquire its Tango and Tango reflex selective laser trabeculoplasty (SLT) lasers, the Ultra Q and Ultra Q Reflex lasers, Integre Pro and Integre Pro Scan lasers, the Eye Prime, Eye One and Eye Cubed ultrasound products and \$66.5 million and \$9.5 million in 2019 revenue and 2019 earnings before interest, tax, depreciation and amortisation (EBITDA) revenue.

The company said Lumibird would also assume ownership of its Adelaide-based manufacturing facility and it expected to complete the transaction by April 2020, subject to shareholder approval.

IDT TERMINATES US TEMOZOLOMIDE MAYNE DISTRIBUTION DEAL

[IDT AUSTRALIA](#)

IDT says it has terminated its Mayne Pharma Group US generic temozolomide product distribution agreement effective immediately and is assessing alternative options.

IMUGENE COMPLETES UNMARKETABLE PARCEL SALE

[IMUGENE](#)

Imugene says it has completed the sale of 5,822,711 unmarketable shares held by 1,048 investors at 2.9 cents a share.

Imugene said it would have 6,430 shareholders, which would reduce ongoing costs.

MICRO-X RAISES \$16.5m IN 'OVERSUBSCRIBED' OFFER

[MICRO-X](#)

Micro-X says it has raised \$16.5 million in an "oversubscribed" placement at 20 cents a share (BD: Nov 19, 2019).

INVION TO SUPPLY DERMATOLOGY COMPOUND FOR CHINA'S PAVAY

[INVION](#)

Invion says its subsidiary Epitech Dermal Science will produce an Australian ingredient for the China-based Pavay Biotech's dermatology products.

TELIX FILES PHASE III TLX250-CDX KIDNEY CANCER FDA IND APPLICATION

[TELIX PHARMACEUTICALS](#)

Telix says it has submitted a phase III Zircon study investigational new drug application to the US Food and Drug Administration for TLX250-CDx for renal cancer imaging.

KAZIA RECEIVES \$1.4m R&D TAX INCENTIVE

[KAZIA THERAPEUTICS](#)

Kazia says it has received \$1,390,849 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Kazia said the rebate related to research and development expenditure for the year to June 30, 2019.

Friday December 27, 2019

ORTHOCELL SHARE PLAN RAISES \$1.4m; TOTAL \$14.4m

[ORTHOCELL](#)

Orthocell says it has raised \$1,423,000 of a hoped for \$5 million in a share purchase plan at 50 cents a share.

Earlier this month, Orthocell said it had commitments for a \$13 million placement at 50 cents a share and hoped to raise a further \$5 million in an underwritten share plan at the same price (BD: Dec 4, 2019).

ALCIDION \$1.9m DEAL WITH DARTFORD, GRAVESHAM NHS TRUST

[ALCIDION GROUP](#)

Alcidion says it has a six year GDP1.02 million (\$A1.9 million) agreement with the UK's Dartford and Gravesham National Health Service Trust

Alcidion said under the agreement, it would implement Better's Openep electronic prescribing and medications administration system for the first time since it was appointed as the reseller and implementer for the UK, Australia and New Zealand.

TELIX SUBMITS TLX591-CDx CLINICAL BRIEFING PACKAGE TO US FDA

[TELIX PHARMACEUTICALS](#)

Telix says it has submitted a complete clinical briefing package to the US Food and Drug Administration for its TLX591-CDx following guidance from its pre-NDA meeting.

DAVID HANNON, DRH SUPER BELOW 5% IN NOXOPHARM

[NOXOPHARM](#)

The Sydney-based David Hannon and DRH Superannuation says it has ceased to be a substantial shareholder in Noxopharm.

DRH said that between April 14, 2018 and December 17, 2019 it bought and sold shares, disposing of 711,237 shares and was diluted in a new issue of shares.

Monday December 30, 2019

PRO MEDICUS, NINES \$6m VISAGE 7 DEAL

[PRO MEDICUS](#)

Pro Medicus says its US subsidiary Visage Imaging has a five-year \$6 million contract with the Palo Alto-based Nines for a Google Cloud Platform-hosted Visage 7 platform. Pro Medicus said the platform would be implemented in the next few weeks and it expected to go live around April 2020.

VISIONEERING \$3m PLACEMENT TO THORNEY

[VISIONEERING TECHNOLOGIES](#)

Visioneering says it has commitments to raise \$3.0 million through a private placement to Thorney Investment Group at 4.5 cents per Chess depositary interest (CDI).

Visioneering said Thorney would nominate a director to join its board, subject to legal and regulatory requirements, and it would extend the maturity date of convertible notes by two years to July 11, 2023 (BD: Jun 6, 2019).

FDA APPROVES AVITA RECELL FOR VITILIGO STUDY

[AVITA MEDICAL](#)

Avita says the US Food and Drug Administration has approved its investigational device exemption application for a Recell for vitiligo safety and efficacy feasibility study.

Avita said it would conduct a 10-patient, 24-week, randomized, controlled pilot study of patients with vitiligo lesions stable for at least one year and would evaluate response rates, optimal suspension parameters and the percentage area of repigmented skin.

DORSAVI RAISES \$187k IN SHARE PLAN; TOTAL RAISED \$1.9m

[DORSAVI](#)

Dorsavi says it has raised \$186,760 of a hoped for \$1.0 million in a share purchase plan at 2.7 cents a share.

Last month, Dorsavi said it had commitments for \$1.7 million in convertible notes and a placement at 2.7 cents a share and hoped to raise a further \$1.0 million in a share purchase plan (BD: Nov 28, 2019).

Dorsavi

STARPHARMA PHASE I AZD0466 TRIAL FOR CANCER; \$4.3m MILESTONE

[STARPHARMA HOLDINGS](#)

Starpharma says it has commenced a phase I trial of AZD0466 for cancers and the dosing of the first patient has triggered a \$US3 million (\$A4,293,600) milestone payment.

Tuesday December 31, 2019 (New Year's Eve)

INVITROCUE TELLS ASX QUERY: DR LINDNER 'NOT THEN A DIRECTOR'

[INVITROCUE](#)

Invitrocue has told the ASX that current director Dr Andreas Lindner and spouse Kathrin bought shares on the days before a major announcement, but Dr Lindner was not a director at the time.

The ASX noted the dates of purchases on January 16 and 17, 2018, followed by the announcement entitled 'IVQ successfully grows liver cancer organoids', published on January 18, which appeared to take place during a closed period, in breach of sections two and three of the trading policy.

Invitrocue said its securities trading policy did not apply to Dr Lindner at the time of the January 2018 transactions, but said Dr Lindner had assured the board he would seek prior approval from the chairman in the future.

Dissident former directors have made a number of accusations against the continuing directors, to which the company responded (BD: Sep 17, 25, Oct 11, 16, 2019).

CRESO DRAWS DOWN \$518k OF CONVERTIBLE NOTE FACILITY

[CRESO PHARMA](#)

Creso says it has drawn down a further \$517,500 under the tranche two convertible note facility and issued additional debt notes worth \$575,000 to L1 Capital Global Opportunities Master Fund (BD: Nov 28, 2019).

Creso said it agreed to amend the conversion price and purchase price to the lesser of 90 percent of the 40-day lowest daily volume weighted average price.

KARST PEAK, VERMILLION, ADAM LEITZES TAKE 12% OF CYCLOPHARM [CYCLOPHARM](#)

Karst Peak Capital, Vermillion Peak Master Fund and Adam Gregory Leitzes say they have become substantial in Cyclopharm with 8,500,000 shares or 12.19 percent.

JENCAY CAPITAL TAKES 6% OF ELLEX [ELLEX MEDICAL LASERS](#)

Jencay Capital says it has increased its substantial shareholding in Ellex from 7,922,445 shares (5.52%) to 9,565,041 shares (6.66%).

The Alexandria, New South Wales-based Jencay said that between August 17 and December 27, 2019 it acquired 1,642,595 shares for \$1,277,483 or 77.8 cents a share.

IMAGION PLEADS SCHULTZ TO 21% ASX PRICE QUERY [IMAGION BIOSYSTEMS](#)

Imagion has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 20.8 percent from 2.4 cents to 2.9 cents today December 31, 2019 and noted a significant increase in the trading volume.

Thursday January 2, 2020

PRESCIENT FOUNDER, DIRECTOR PAUL HOPPER STEPS DOWN [PRESCIENT THERAPEUTICS](#)

Prescient says founder and non-executive director Paul Hopper has stepped down "to pursue other business interests".

NUHEARA APPOINTS CHERYL EDWARDES CHAIR [NUHEARA](#)

Nuheara says it has appointed former Western Australian attorney general Cheryl Edwardes as its non-executive chair.

REDHILL ENDS 2014 SALIX LICENCE [REDHILL BIOPHARMA](#)

Redhill says it has terminated its 2014 licence with Salix Pharmaceuticals regaining worldwide rights to RHB-106 for bowel preparation, currently in development.

AUSTRALIAN ETHICAL TAKES 10% OF CYCLOPHARM [CYCLOPHARM](#)

Australian Ethical Investment says its substantial holding in Cyclopharm has increased and been diluted from 7,881,168 shares (11.46%) to 8,088,276 shares (10.34%).

Australian Ethical said that between August 13, 2018 and December 10, 2019 it bought 207,108 shares for \$195,285 or an average 94.3 cents a share.

CVC REDUCES TO 9% OF CYCLOPHARM [CYCLOPHARM](#)

CVC says it has reduced its substantial shareholding in Cyclopharm from 7,142,729 shares (10.39%) to 6,965,868 shares (8.90%).

The Sydney-based CVC said it was diluted in Cyclopharm's \$9,775,000 placement (BD: Dec 20, 2019).

MESOBLAST FILES FDA REMESTEMCEL-L DATA

[MESOBLAST](#)

Mesoblast says the US Food and Drug Administration has received clinical efficacy and safety data for its biologics licence application for remestemcel-L.

Mesoblast said the final module would be filed in January 2020, and it would request an expedited FDA review of the application under its fast track designation for steroid-refractory acute graft versus host disease, and it planned to launch in the US this year.

Friday January 3, 2020

ANTISENSE OPTIONS RAISE \$5.5m

[ANTISENSE THERAPEUTICS](#)

Antisense says it raised \$5.5 million through the underwritten conversion of listed options which expired on December 19, 2019, for a phase IIb trial of ATL1102 for Duchenne muscular dystrophy.

ROBERT BAZZANI REPLACES MACH7'S DAMIEN LIM, JENNIFER PILCHER

[MACH7 TECHNOLOGIES](#)

Mach7 says it has appointed Robert Bazzani as a non-executive director, replacing Damien Lim as a non-executive director, with Jennifer Pilcher stepping down as interim director to resume her role as chief financial officer and company secretary.

ADALTA LOSES DIRECTOR DR JOHN CHIPLIN

[ADALTA](#)

Adalta says non-executive director Dr John Chiplin has retired and it won't appoint a replacement director.

Monday January 6, 2020

USCOM 5-YEAR CHINA NMPA APPROVAL FOR USCOM 1A

[USCOM](#)

Uscom says it has a five-year China National Medical Products Administration regulatory extension certification for its ultra-sonic cardiac output monitor Uscom 1A in China, valid until December 22, 2024.

CELLMID US, EURO MIDKINE PATENTS

[CELLMID](#)

Cellmid says it has received US and European patents for improved midkine antibodies, which will protect its intellectual property until October 14, 2035.

NUHEARA LAUNCHES IQBUDS MAX, TO BEGIN SHIPPING IN MARCH

[NUHEARA](#)

Nuheara says it has launched its Iqbuds Max hearing buds for preorder and will commence shipping in March.

Tuesday January 7, 2020

OPTHEA RECRUITS OPT-302 COMBO TRIAL FOR DME

[OPTHEA](#)

Opthea says it has completed recruitment of its 108-patient phase IIa trial of OPT-302 with aflibercept or Eylea for diabetic macular oedema.

PHARMAUST EPICHEM CLIENT UNITY BIOTECHNOLOGY ENDS CONTRACT

[PHARMAUST](#)

Pharmaust says a client of its subsidiary Epichem, Unity Biotechnology Inc will end its contract in February “due to funding issues at Unity”.

POLYNOVO: '\$2m NOVOSORB BTM DECEMBER SALES'

[POLYNOVO](#)

Polynovo says it received \$2 million in sales of its Novosorb BTM in December 2019, its first two-million-dollar month, up 134 percent from \$890,000 in December 2018.

MGC AUSTRALIA, NEW ZEALAND MARIJUANA MERCURY PHARMA

[MGC PHARMACEUTICALS](#)

MGC says it has launched an “affordable” prescription marijuana line, Mercury Pharma, for Australia and New Zealand.

MGC said its first cannabidiol (CBD) 100 milligram/milliliter product, Mercury Pharma 100 or MP100 would be distributed by Cannvalate and Health House International, with initial purchase orders for more than 2,000 units to be delivered in January and February.

CYNATA RECEIVES \$1.9m R&D TAX INCENTIVE

[CYNATA THERAPEUTICS](#)

Cynata says it has received \$1,891,795 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Cynata said the rebate related to research and development expenditure for the year to June 30, 2019.

DIMERIX 'NO SAFETY CONCERNS IN DMX-200 TRIALS'

[DIMERIX](#)

Dimerix says an independent safety review committee has not identified safety concerns in a review of its phase II trials of DMX-200 for focal segmental glomerulosclerosis and diabetic kidney disease.

CANN GROUP, IDT MARIJUANA RESIN EXTRACTION UNDERWAY

[CANN GROUP, IDT AUSTRALIA](#)

IDT and Cann Group say extraction activities are underway for the first batches of marijuana resin, an active pharmaceutical ingredient in IDT's cannabis oil products.

ALTHEA BEATS 4k MARIJUANA PATIENT TARGET

[ALTHEA GROUP](#)

Althea says it has exceeded its 4,000-patient year-end target by 18 patients and prescribed an average of 36 patients a day in December, up 48 percent.

Wednesday January 8, 2020

PHARMAUST EPICHEM EXTENDS DNDI CONTRACT TO DEC 31, 2020

[PHARMAUST](#)

Pharmaust says subsidiary Epichem expects to generate \$1.24 million in revenue from an extension to its Drugs for Neglected Diseases Initiative contract to the end of 2020.

ELIXINOL RELEASES 78m SHARES FROM ASX ESCROW

[ELIXINOL GLOBAL](#)

Elixinol says it has released 77,870,572 shares previously held under ASX escrow. According to its most recent Appendix 3B new issue announcement, Elixinol would have 137,894,112 shares quoted on the ASX following the release from escrow.

CRESO PLEADS SCHULTZ TO ASX 24% QUERY

[CRESO PHARMA](#)

Creso has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 24.0 percent from 12.5 cents on December 31, 2019 to 15.5 cents on January 7, 2020 and noted a significant increase in the trading volume.

CRESO RELEASES 500k SHARES FROM VOLUNTARY ESCROW

[CRESO PHARMA](#)

Creso says 500,000 shares will be released from voluntary escrow on January 16, 2020.

Thursday January 9, 2020

IMMUTEP EXPANDS IMP321 TACTI-002 CANCER STUDY

[IMMUTEP](#)

Immutep says the requisite number of patient responses were observed in stage one of part C of its Tacti-002 phase II study of eftilagimod alpha or IMP321 for cancers. Immutep said following the recruitment of 18 head and neck squamous cell carcinoma patients for stage one, it would now recruit a further 19 patients for stage two.

ADHERIUM APPOINTS JANE LAPON MARKET ACCESS HEAD

[ADHERIUM](#)

Adherium says it has appointed Jane Lapon as head of market access and reimbursement.

Adherium

MGC: 2k MARIJUANA SCRIPTS; 1st SHIPMENT IN BRAZIL

[MGC PHARMACEUTICALS](#)

MGC says it has passed 2,000 prescribed units of its cannabinoid medicines from patients in Australia, the UK, Brazil and Ireland.

MGC said its first shipment to Onix Empreendimentos e Participações arrived in Brazil in November 2019.

Friday January 10, 2020

ELI LILLY PAYS \$1.6b FOR TOM WIGGANS' DERMIRA

[DERMIRA](#)

Dermira executive chairman Tom Wiggans says that Eli Lilly & Co will buy his company for \$1.1 billion for its portfolio of phase III medicines.

Mr Wiggans was previously the chairman and chief executive officer of Brisbane's Peplin which was acquired in 2009 by Denmark's Leo Pharma for \$348 million for its PEP005 Gel for actinic keratosis and other pre-cancerous lesions.

Dermira said that lebrikizumab was an interleukin-13 (IL-13) antibody in phase III studies for moderate-to-severe atopic dermatitis, along with its Qbrexza medicated cloth for primary axillary hyperhidrosis or uncontrolled excessive underarm sweating.

THORNEY, TIGA TRADING TAKE 15% OF VISIONEERING

[VISIONEERING TECHNOLOGIES](#)

Thorney Technologies and Tiga Trading say they have increased their shareholding in Visioneering from 28,829,865 shares (10.64%) to 70,649,514 shares (15.17%).

The Melbourne-based Thorney and Tiga said that on July 5, 2019 they acquired 13,656,251 shares in a nine-for-19 rights issue at 4.5 cents a share, between October 8 and November 20 acquired 903,262 shares at 10.5 and 9.6 cents a share and on January 8, 2020 acquired 29,066,660 shares at 4.5 cents a share.

REGAL FUNDS INCREASES, DILUTED TO 14% OF VISIONEERING

[VISIONEERING TECHNOLOGIES](#)

Regal Funds Management says it has increased and been diluted in Visioneering from 61,734,060 shares (15.47%) to 64,626,403 shares (13.87%).

The Sydney-based Regal Funds said that between July 5, 2019 and January 8, 2020 it sold 792,477 shares for \$47,660.90 or an average of 6.0 cents a share and on January 8 bought 3,684,820 shares for \$165,816.90 or 4.5 cents a share and was diluted.

Monday January 13, 2020

ANDREAS EMPL REPLACES LIFESPOT DIRECTOR GREG PLUNKETT

[LIFESPOT HEALTH](#)

Lifespot says it has appointed Andreas Empl as a non-executive director and director Greg Plunkett has resigned "in order to focus on his other business commitments".

Lifespot said Mr Plunkett would continue to consult as required.

AVECHO: EX-BIOSCIENCE MANAGERS MATT MCNAMARA DIRECTOR

[AVECHO BIOTECHNOLOGY](#)

Avecho says it has appointed former Bioscience Managers chief investment officer Matthew McNamara as a non-executive director effective from January 13, 2020.

Avecho said that Mr McNamara was a current director of Adherium, Scicapital Pty Ltd and Grey Innovation, and a former director of Avita, Bioxyne and Rex Bionics.

ESENSE APPOINTS DR JAMES ELLINGFORD DIRECTOR

[ESENSE-LAB](#)

Esense-Lab says it has appointed Dr James Ellingford as a non-executive director and chairman Piers Lewis has become a non-executive director.

TOTAL BRAIN APPOINTS DAVID DAGLIO DIRECTOR

[TOTAL BRAIN](#)

Total Brain says it has appointed David Daglio as a non-executive director effective from January 13, 2020.

ANTEOTECH PLEADS SCHULTZ TO ASX 72% QUERY

[ANTEOTECH \(FORMERLY ANTEO DIAGNOSTICS\)](#)

Anteotech has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 72.2 percent from 1.8 cents on December 27, 2019 to 3.1 cents on January 10, 2020 and noted a significant increase in the trading volume.

ANGLO CHARITABLE INCREASES, DILUTED TO 17% OF CYCLOPHARM

[CYCLOPHARM](#)

Anglo Australian Christian and Charitable Fund says it has increased and been diluted in Cyclopharm from 11,517,600 shares (19.28%) to 13,211,332 shares (16.89%).

The London-based Anglo Charitable Fund said that it acquired 1,693,732 shares on June 30, 2017 for \$1,354,986 or 80.0 cents a share and was diluted on December 31, 2019 in a \$9.8 million institutional placement (BD: Dec 20. 2019).

RACE DR AL-BEHAISI CONTRACT ENDS; TO RECRUIT AUSTRALIAN CRM

[RACE ONCOLOGY](#)

Race says its Europe-based consulting contract with Dr Samar Al-Behaisi as chief medical officer and vice president of medical affairs will conclude on March 20, 2020. Race said it would recruit an Australia-based clinical research manager.

Tuesday January 14, 2020

MMJ \$2.2m HARVEST ONE CANNABIS LOAN AGREEMENT

[MMJ GROUP HOLDINGS](#)

MMJ says it has a \$2 million (\$A2.2 million) secured loan agreement with Harvest One Cannabis Inc, which would be used for Harvest One general corporate purposes. MMJ said the interest rate was 15 percent a year, payable in arrears within 60 days of the issue date, and it would receive a security interest in all Harvest One property.

UK APPROVES CYNATA CYMERUS CRITICAL LIMB ISCHAEMIA TRIAL

[CYNATA THERAPEUTICS](#)

Cynata says the UK Medicines and Healthcare Products Regulatory Agency has approved a phase II trial of its Cymerus mesenchymal stem cell CYP-002 for critical limb ischaemia.

CE MARK FOR PROTEOMICS PROMARKERD HUB

[PROTEOMICS INTERNATIONAL LABORATORIES](#)

Proteomics says it has Conformité Européenne (CE) mark registration for its Promarkerd Hub as an in-vitro diagnostic device for kidney disease in type 2 diabetes patients.

ADALTA PHASE I AD-214 TRIAL DELAYED FOR MORE DATA

[ADALTA](#)

Adalta says its phase I human clinical trial of AD-214 will now include both healthy volunteers and idiopathic pulmonary fibrosis-interstitial lung disease patients. Adalta said it would incorporate a radio-labelled version of AD-214 and would conduct an additional pre-clinical study “in lieu of a second half 2019 study that was unable to generate results in any arm of the study”, following a review of all pre-clinical data. The company said these changes would lead to a four to five-month delay to the start of the phase I trial to mid-2020.

EURO ORPHAN STATUS FOR ALTERITY PBT434 FOR MSA

[ALTERITY THERAPEUTICS](#)

Alterity says the European Commission has granted orphan drug designation for PBT434 for multiple system atrophy.

Alterity said it would be entitled to 10 years of market exclusivity in the European Union, assistance in developing clinical protocols, reduced fees and access to research grants.

IMUGENE: US GRANTS HER-VAXX CANCER IMMUNOTHERAPY PATENT

[IMUGENE](#)

Imugene says the US Patent and Trademark Office has granted a patent for its HER-Vaxx cancer immunotherapy, in phase II development for gastric cancer.

Imugene said the patent, titled ‘A vaccine composition and uses thereof’ would protect its intellectual property until 2036.

ESCROW END TAKES RAW WITH LIFE, ELIXINOL’S PAUL BENHAIM TO 40%

[ELIXINOL GLOBAL](#)

Raw with Life, as trustee for Benhaim Trading Trust, says it has reduced its holding in Elixinol from 77,870,572 shares (56.47%) to 54,623,008 shares (39.61%).

The Murwillumbah, New South Wales-based Raw with Life said the reduction was due to the release of shares from escrow on January 8, 2020.

Mr Benhaim previously told Biotech Daily that his personal holding of 54,623,008 shares was unchanged.

INVESTORS MUTUAL REDUCES TO 6% OF ELLEX

[ELLEX MEDICAL LASERS](#)

Investors Mutual says it has reduced its substantial shareholding in Ellex from 10,397,315 shares (7.24%) to 8,932,315 shares (6.22%).

The Sydney-based Investors Mutual said that between December 24, 2019 and January 14, 2020 it sold 1,465,000 shares, with the single largest sale 300,000 shares for \$847,650 or \$2.8255 a share, when the company was trading at 79 to 81 cents.

KARST PEAK, ADAM LEITZES, VERMILLION REDUCE TO 6% OF AVITA

[AVITA MEDICAL](#)

Karst Peak Capital, Adam Gregory Leitzes and Vermillion Peak Master Fund say they have reduced their holding in Avita from 149,478,250 shares (7.06%) to 128,305,459 shares (6.06%).

Karst Peak said it sold the shares between November 9, 2019 and January 7, 2020 at prices ranging from 51.69 cents to 65.16 cents a share.

PHARMAUST RECEIVES \$713k R&D TAX INCENTIVE

[PHARMAUST](#)

Pharmaust says it has received \$712,647 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Pharmaust said the rebate related to research and development expenditure for the year to June 30, 2019.

GI DYNAMICS RECEIVES \$6.7m FROM CRYSTAL AMBER CONVERTIBLE NOTE

[GI DYNAMICS](#)

GI Dynamics says it has received \$US4,596,893 (\$A6,680,182) from Crystal Amber Fund under the convertible note issued to Crystal Amber last year (BD: Aug 22, 2019).

Wednesday January 15, 2020

REVA FILES US CH 11 BANKRUPTCY

[REVA MEDICAL](#)

Reva says it has filed for US Chapter 11 bankruptcy protection due to its insolvent cash position.

The company said that “all equity interests and share equivalents are worthless”.

GI DYNAMICS: ENDOBARRIER ‘SIGNIFICANTLY’ REDUCES C-V RISK

[GI DYNAMICS](#)

GI Dynamics says a 71-patient trial of type 2 diabetes and metabolic syndrome patients shows its Endobarrier reduces cardiovascular risk “significantly”.

GI Dynamics said improvements in haemoglobin A1c (HbA1c), body mass index (BMI), fasting plasma glucose, homeostatic model assessment score or insulin resistance, total cholesterol and lipoprotein-associated phospholipase A2 (Lp-PLA2) were statistically significant during implant and below baseline at six months post-explant. The company said overall cardiovascular risk decreased “significantly” following implantation and remained stable at six months explant.

KARIN LINDGREN REPLACES VOLPARA DIRECTOR PROF MIKE BRADY

[VOLPARA HEALTH TECHNOLOGIES](#)

Volpara says it has appointed Karin Lindgren as a non-executive director and director Prof Mike Brady will retire effective from January 31, 2020.

BARINGS DILUTED TO 15% OF CYCLOPHARM

[CYCLOPHARM](#)

Barings Acceptance says its 11,433,424 shareholding in Cyclopharm has been diluted from 16.66 percent to 14.61 percent.

The London-based Barings said that it was diluted on December 31, 2019 in a \$9.8 million institutional share placement (BD: Dec 20, 2019).

ALTERITY RECEIVES \$4.8m R&D TAX INCENTIVE

[ALTERITY THERAPEUTICS](#)

Alterity receives \$4,824,880 from the Australian Tax Officer under the Federal Government Research and Development Tax Incentive program.

Alterity said the rebate related to research and development expenditure for the year to June 30, 2019.

ORTHOCELL RECEIVES \$2.9m R&D TAX INCENTIVE

[ORTHOCELL](#)

Orthocell says it has received \$2,904,545 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program. Orthocell said the rebate related to research and development expenditure for the year to June 30, 2019.

JAPAN PATENT FOR PAINCHEK SMART PHONE PAIN TEST

[PAINCHEK](#)

Painchek says it has been granted a Japanese patent for its smart phone pain assessment and monitoring smartphone application.

TALI: GOOGLE FOR EDUCATION PARTNER STATUS

[TALI DIGITAL \(FORMERLY NOVITA HEALTHCARE, AVEXA\)](#)

Tali Digital says it has Google For Education Partner status and its Tali Detect and Tali Train will be available via Google products including G Suite.

Tali Digital said it would also access technical support from Google developers as its products meets the requirements to be a priority for Google features.

NAOS TAKES 22% OF BTC HEALTH

[BTC HEALTH](#)

Naos Asset Management says it has increased its substantial shareholding in BTC from 48,165,801 shares (19.65%) to 53,035,248 shares (21.55%).

The Sydney-based Naos said that on January 15, 2020 it acquired 4,869,447 shares on-market.

STEMCELL UNITED PLEADS SCHULTZ TO ASX 85% QUERY

[STEMCELL UNITED](#)

Stemcell United has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 84.6 percent from 1.3 cents to 2.4 cents on January 15, 2020 and noted a significant increase in the trading volume.

Thursday January 16, 2020

ASX QUERIES VISIONEERING CASH BURN

[VISIONEERING TECHNOLOGIES](#)

Visioneering has told the ASX that it expects to have negative operating cash flows "for the time being".

The ASX said the Visioneering Appendix 4C quarterly report included a cash burn of \$2,927,000 for the three months to December 31, 2019, with cash of \$1,919,000 and an expected cash burn for the three months to March 31, 2020 of \$4,300,000, and asked the company if it expected to continue having negative operating cash flows, what steps it had or would take to fund its operations and how it expected to continue operations.

Visioneering said it was seeking funding through "a number of channels" and believed it would secure additional capital by April 2020 but expected its current cash to be sufficient to fund operations until May 2020.

NOXOPHARM'S NYRADA IPO OPENS UP 52.5%

[NYRADA](#)

Noxopharm spin-out Nyrada opened 52.5 percent above its 20-cent initial public offer at 30.5 cents, having raised \$8.5 million for cholesterol and pain drug development. Nyrada closed its first trading session up 17.5 percent at 23.5 cents with 5.7 million shares traded.

LIFESPOT CAPITAL AG REDUCES TO 18% OF LIFESPOT

[LIFESPOT HEALTH](#)

Lifespot Capital AG says it has reduced its substantial shareholding in Lifespot from 19,797,126 shares (25.52%) to 14,157,126 shares (18.25%). The Munich, Germany-based Lifespot Capital said that it transferred 5,640,000 shares off-market between August 29, 2019 and January 3, 2020 for \$189,098 or an average of 3.4 cents a share.

Friday January 17, 2020

G MEDICAL COMPLETES CHINA TRIALS FOR PRIZMA APPROVAL

[G MEDICAL INNOVATIONS HOLDINGS](#)

G Medical says it has completed the clinical trials required for China National Medical Products Administration approval of its Prizma device.

OBJ 'WELLFULLY' \$50m BACKDOOR, 20-TO-ONE CONSOLIDATION EGM

[OBJ](#)

OBJ says shareholders will vote on an \$85 million Export Corp Nutrition Systems backdoor listing, change its name to Wellfully and conduct a 20-to-one consolidation. OBJ said Export Corp vendor and chief executive officer of its subsidiary Nutrition Systems Danny Pavlovich would be appointed a director.

The company said the acquisition would change the nature of its "main activities from a pharmaceuticals, biotechnology and life sciences company to a vertically integrated, science-based wellness company" for \$50 million in cash and \$35 million in equity. OBJ said that the extraordinary general meeting would vote to issue up to 145,833,334 shares on a post-consolidation basis to the vendor, up to 116,666,667 shares as part of a capital raising, up to 3,333,334 shares each to Steven Schaperia and Antonio Varano, and up to 1,666,667 shares each to Jeffrey Edwards, Christopher Quirk and Cameron Reynolds as related parties.

The meeting will be held at RSM Perth, Sir Cyril Bird Boardroom, Level 2 Exchange Tower, 2 The Esplanade, Perth on February 18, 2020 at 10am (AWST).

MERCHANT FUNDS MANAGEMENT BELOW 5% IN ZELIRA

[ZELIRA THERAPEUTICS](#)

Merchant Funds Management says it has ceased to be a substantial shareholding in Zelira.

The Perth, Western Australia-based Merchant said that it was diluted on January 2, 2020 due to an issue of shares by Zelira.